皮尔芬尼和宁泰达尼布在肺纤维化中的作用:光与阴影
Maria Chianese1, Gianluca Screm1, Francesco Salton1
1Pulmonology Unit, Department of Medical Surgical and Health Sciences, University of Trieste, Hospital of Cattinara, 34149 Trieste, Italy.
Pharmaceuticals (Basel, Switzerland)
|June 27, 2024
概括
皮尔费尼和宁泰达尼布有效治疗纤维化间歇性肺病 (ILD),包括异常性肺纤维化 (IPF). 然而,控制其副作用对于患者的治疗结果至关重要,需要进一步研究以优化抗纤维菌疗法.
科学领域:
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
- 医学研究 医学研究
背景情况:
- 异形性肺纤维化 (IPF) 和其他纤维化间歇性肺病 (ILD) 是一种渐进的疾病.
- 皮尔费尼和宁泰达尼布是已批准的抗纤维菌疗法,在减缓疾病进展方面表现出有效性.
研究的目的:
- 审查Pirfenidone和Nintedanib在各种ILD中的有效性和不良事件.
- 突出管理治疗相关副作用的挑战.
主要方法:
- 在PubMed,UpToDate,谷歌学者和ResearchGate (2018-2023) 的系统文献搜索.
- 关键词包括Pirfenidone,Nintedanib,ILD和IPF. 这些药物是最常见的.
- 评估疾病进展主要通过强迫生命能力 (FVC) 的下降.
主要成果:
- 皮尔芬尼和宁泰达尼布都在治疗纤维化ILD方面表现出有效性.
- 常见的副作用包括胃肠道问题 (腹,消化不良,吐) 和皮肤反应 (光敏感性,皮疹),特别是Pirfenidone.
- 对于严重的,危及生命的副作用,可能需要停止治疗.
结论:
- 抗纤维素剂Pirfenidone和Nintedanib可以减缓ILD的进展,并可能降低死亡率.
- 进一步的研究是必要的,以优化抗纤维素治疗,并确定治疗方法,以停止ILD的进展.
- 精心管理副作用对于成功的长期治疗至关重要.
相关概念视频
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
157
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
166
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
166
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
152
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
152
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
146
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
146
01:25Pulmonary Function Tests
317
Pulmonary Function Tests (PFTs)
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
317
01:28Pulmonary Tuberculosis V
177
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
177